Fluconazole orally dispersible tablets for the treatment of patients with oropharyngeal candidiasis
| Autor: | Bernard Vandercam, H Jäger, David L. Gibbs, O Armignacco, M Valtonen |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Antifungal Agents medicine.medical_treatment Administration Oral 030204 cardiovascular system & hematology Biochemistry Gastroenterology Oropharyngeal Candidiasis 03 medical and health sciences 0302 clinical medicine Candidiasis Oral Internal medicine Candida albicans medicine Humans Adverse effect Sida Fluconazole Mycosis Chemotherapy biology business.industry Biochemistry (medical) Cell Biology General Medicine Middle Aged biology.organism_classification medicine.disease Surgery Tolerability 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | The Journal of international medical research. 26(4) |
| ISSN: | 0300-0605 |
| Popis: | The efficacy and tolerability of fluconazole orally dispersible tablets (ODT) in the treatment of oropharyngeal candidiasis was evaluated in this multicentre non-comparative study. A total of 89 adults with signs and symptoms of oropharyngeal candidiasis were enrolled; 70 of whom completed therapy with fluconazole ODT 100 mg once daily for 7–14 days. Acquired immunodeficiency syndrome (AIDS)/ AIDS-related complex was an underlying illness in 69% of patients (61). An antimicrobial and corticosteroid therapy was given in 52% (46) and 20% (18) of patients, respectively. Of the 60 patients who had baseline signs and symptoms of infection and a culture positive for Candida albicans, 90% (54) were cured or had improved at the end of therapy, and the fungal pathogen was eradicated in 19/57 (33%) patients. At the 4-week post-treatment follow-up, signs and symptoms of oropharyngeal candidiasis were absent in 73% (27/37) patients. The adverse events and laboratory abnormalities recorded during the study period were attributable to underlying illnesses rather than to fluconazole therapy. These results indicate that this novel dosage form of fluconazole is effective and well tolerated in the treatment of oropharyngeal candidiasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|